A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection Versus Amiodarone in Subjects With Recent Onset Atrial Fibrillation.

Trial Profile

A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection Versus Amiodarone in Subjects With Recent Onset Atrial Fibrillation.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Vernakalant (Primary) ; Amiodarone
  • Indications Atrial fibrillation
  • Focus Registrational; Therapeutic Use
  • Acronyms AVRO
  • Most Recent Events

    • 29 Jun 2012 Company added in the association field as reported by EudraCT.
    • 29 Jun 2012 Additional trial location (Latvia) identified as reported by EudraCT.
    • 24 Mar 2012 This trial is recruiting in France.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top